IntegraGen is dedicated to gene discovery and the commercialization of molecular diagnostics products and services that provide clinicians with new tools to personalize diagnosis, treatment, and therapy.

IntegraGen has expanded beyond its roots as a research entity into a biotech company, leveraging its powerful proprietary technology GenomeHIP^TM. IntegraGen is focused on the prevention and proactive management of complex debilitating diseases, and dedicated to addressing the needs of patients, clinicians, and advocacy groups. Supported by strong intellectual property and impressive gene discovery capabilities and external partners, we are nearing the launch of our first internally developed molecular diagnostic test. With strong pre-clinical validation behind us, we have recently completed a clinical trial for a risk-predictive test for Autism.

With discovery and intellectual property focused on diabetes, obesity,  bipolar disorders, schizophrenia, and autism, we are committed to delivering products and services that empower by enabling preemptive and more effective interventions. Driven by innovation, we are keenly aware of our responsibility to patients, medical professionals, partners, and investors. Integrity, respect, and excellence are fundamentals behind all of our actions. We are confident in our ability to deliver ground breaking offerings, and proud that they will improve quality of life.

Bernard Courtieu
Chief Executive Officer